Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.67 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24095454 | 0.87 | TGFBR1 (0.78) | TGFBR1MAP3K12KCNH2TNIK | |
| SCHEMBL24095521 | 0.84 | TGFBR1 (0.64) | TGFBR1MAP3K12KCNH2TNIKCNR2 | |
| SCHEMBL24095456 | 0.84 | TGFBR1 (0.64) | TGFBR1MAP3K12KCNH2TNIKCNR2 | |
| SCHEMBL24095396 | 0.83 | TGFBR1 (0.51) | TGFBR1 | |
| SCHEMBL24095463 | 0.82 | TGFBR1 (0.75) | TGFBR1MAP3K12KCNH2TNIKCNR2 | |
| SCHEMBL24095514 | 0.81 | TGFBR1 (0.77) | TGFBR1MAP3K12 | |
| SCHEMBL22851103 | 0.80 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL17645440 | 0.76 | TGFBR1 (0.72) | TGFBR1 | |
| SCHEMBL24095512 | 0.75 | TGFBR1 (0.42) | TGFBR1 | |
| SCHEMBL24298553 | 0.73 | TGFBR1 (0.61) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3922631-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-BETA R1 KINASE INHIBITOR | Jiangsu AoSaiKang Pharmaceutical Co., Ltd. (CN) | 2021-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAP3K12 63/4885KCNH2 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.